Search Results

In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia of D2R signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical

Hannes Schihada Following studies in Pharmacy in Regensburg, Germany, I joined the receptor pharmacology group of Martin Lohse at the Institute of Pharmacology & Toxicology in Würzburg, Germany, in 2015. By the end of 2021, I moved back to Germany and joined the pharmaceutical chemistry group of Peter Kolb

His lab focuses on developing and innovating technologies to solve broad questions in pharmacology, with

and Better Medicines Theme Leader of the Neuromedicines Discovery Centre at the Monash Institute of Pharmaceutical He has a degree and PhD in pharmacology from Queens' College, Cambridge and University College London in 2012, and was the recipient of the British Pharmacological Society Novartis Prize in 2017. Chris serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience , ACS Pharmacology & Translational Science and Frontiers in Pharmacology.

In his latest lesson, he breaks down the essential models shaping modern pharmacology. ✳️ https://www.terrykenakin.com #pharmacology #drugmechanism #kenakin #GPCR #DrGPCR Previous Next Recent

to Target Pain Management About Émile Breault "Emile Breault is undertaking his master's degree in pharmacology He recently received his BSc in pharmacology from the University of Sherbrooke in 2023.

training at the University of New South Wales (UNSW) Sydney, Australia in 2016 with first class Honours in Pharmacology This project aims to characterise the molecular pharmacology of GPR146 and to validate the proposed ligands

Maudsley Stuart graduated from the University of Leeds in the U.K. with a First Class Honors degree in Pharmacology To broaden his biomedical skill-set Stuart next accepted the position of Head of the Receptor Pharmacology

Ajay Yekkirala is a GPCR pharmacologist, biotech entrepreneur, and co-founder of Superluminal Medicines strategic leaders seeking new drug development models Anyone curious about where AI meets molecular pharmacology Ajay Yekkirala is a molecular pharmacologist, biotech founder, and scientist whose career has been defined rejection letter pivoted him into a PhD program at the University of Iowa, where he studied opioid pharmacology

He subsequently returned to Munich as a research associate at the Institute of Pharmaceutical Chemistry Habilitus, he was appointed at the University of Bonn as a Professor of Pharmaceutical Chemistry declining Peter has been chaired Full Professor of Pharmaceutical / Medicinal Chemistry at the Friedrich-Alexander University Erlangen-Nürnberg and declined an offer for the Chair for Pharmaceutical Chemistry at the

In his (future) independent research career, Aditya aims to work at the interface of GPCR molecular pharmacology

Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University initially became interested in GPCR signal transduction during my graduate training in the Department of Pharmacology

Soon About Louis Gendron "Dr Louis Gendron, PhD is tenured Professor and Chair of the Department of Pharmacology-Physiology He has 20+ years of experience in in vitro and in vivo GPCR pharmacology and has published seminal papers

University Medical Center Hamburg-Eppendorf" About Anastasia Georgiadi "Head of Junior Group Endocrine Pharmacology Cell and Molecular Biology, Karolinska Institute, Sweden" Anastasia Georgiadi on the web Endocrine Pharmacology In all, research in the Tilley lab spans molecular pharmacology to pathophysiology studies focused primarily

Adriano received his Bachelor of Science degree in Pharmacology in 1991 from the University of Toronto his graduate studies at the University of Toronto where he earned his MSc (1994) and Ph.D. (1998) in Pharmacology In 2004 Adriano joined the faculty of the Department of Pharmacology at Loyola University Chicago.

He is a 2022 Clarivate Analytics Highly Cited Researcher in two disciplines: Pharmacology & Toxicology corresponding member of NC-IUPHAR, a member of the Faculty of 1000 and an elected Fellow of the British Pharmacological

Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. In addition to paradigm shifts including inverse agonism, biased signaling, and pharmacological chaperones fellow of the Royal Society of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology

Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology

Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009. He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

In April 2009, he joined the Department of Pharmacology and Toxicology at University of Toronto and has

Jacek Mokrosiński "Jacek is a Senior Scientist at Novo Nordisk specializing in molecular pharmacology

ranks at Warwick to become an Associate Professor before leaving in 2015 to join the Department of Pharmacology In 2020, he was promoted to a Readership/Professor in Receptor Pharmacology and was elected a Fellow of the British Pharmacological Society. His research group uses a combination of pharmacological investigations and mathematical modeling to These investigations have enabled him to foster strong collaborations with the pharmaceutical industry

When the pharmacological properties of these new ligands are deemed exceptional, a lead optimization

Katarina Nemec " I am a pharmacist with an interest in systems pharmacology and precision medicine. I studied Pharmacy at the University in Ljubljana, Slovenia, and at the University of Bonn, Germany, studies in Martin Lohse lab at the Max Delbrueck Center in Berlin, I consolidated my knowledge of GPCRs pharmacology discovery and adopt data science methodology to tackle relevant scientific questions on the systems pharmacology

GPCR University GPCR Insights in Action Transform complex pharmacology into clear, practical understanding

Subsequent work has focused on understanding the molecular basis of GPCR pharmacology through structure

10 years of experience in the development and management of R&D projects and teams in the field of pharmacology I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role

elegant mechanistic biology with translational impact — giving us new ways to think about receptor pharmacology GPCR Premium → https://www.ecosystem.drgpcr.com/gpcr-university #GPCR #DrGPCR #pharmacology #drugdiscovery

Biology in 1996 as a postdoc and becoming faculty at Duke in 2000, he researched at the Institute of Pharmacology He received a Ph.D. in pharmacology in 1992 from the Russian Academy of Medical Sciences and an M.D. Chair of the subcommittee for the Dopamine receptors of the International Union of Basic and Clinical Pharmacology

Why targeting the pharmacologically relevant surface-exposed receptor pool changes the way scientists These years shaped his interest in ion channels, GPCR pharmacology, and the chemical strategies needed Since 2020, JB has led his research group at the Leibniz Research Institute for Molecular Pharmacology Broichhagen on the Web LinkedIn Google Scholar Lab Website Leibniz Research Institute for Molecular Pharmacology